OncoMatch/Clinical Trials/NCT04927780
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
Is NCT04927780 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Leucovorin Calcium and Fluorouracil for pancreatic cancer.
Treatment: Leucovorin Calcium · Fluorouracil · Irinotecan Hydrochloride · Oxaliplatin — The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
WHO 0–1
Prior therapy
Cannot have received: radiotherapy
Prior radiotherapy ... for pancreatic cancer.
Cannot have received: chemotherapy
Prior ... chemotherapy ... for pancreatic cancer.
Cannot have received: surgery
Prior ... surgery for pancreatic cancer.
Cannot have received: chemotherapy precluding mFOLFIRINOX
Prior chemotherapy precluding mFOLFIRINOX.
Lab requirements
Blood counts
leucocytes (wbc) ≥ 3.0 x 10^9/l; platelets ≥ 100 x 10^9/l; hemoglobin ≥ 6.0 mmol/l
Kidney function
egfr ≥ 40 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify